Pfizer closes Hospira Acquisition - can it trigger a SPLIT?

[anonymous]

Don't get too comfortable Hospira!

The WORST may be yet to come!

http://www.bidnessetc.com/51856-pfizer-inc-closes-hospira-inc-acquisition-can-it-trigger-a-split/

 

[anonymous]

Everyone from Hospira is about to be split from their employment into the unemployment line.

 

[anonymous]

The Pfizer GEP split of its core business was discussed here several times and numerous times on web for the LAST YEAR it's nothing new They call Mike Ball back out of retirement to run it

HR

 

[anonymous]

There is no happy ever after as Pfizer has planned all along to spin off everything they acquired from Hospira in 2 years with all their end of life drugs, with exception of the biosimilar drugs, which was the ONLY reason they bought Hospira in the first place. The smart move would be to get your resumes updated soon, as the future is unpredictable at best!

 

[anonymous]

There is no happy ever after as Pfizer has planned all along to spin off everything they acquired from Hospira in 2 years with all their end of life drugs, with exception of the biosimilar drugs, which was the ONLY reason they bought Hospira in the first place. The smart move would be to get your resumes updated soon, as the future is unpredictable at best!

Agreed. I am out and not really regretting the decision at all.

 

[anonymous]

Information for Hospira Shareholders

On September 3, 2015, Hospira’s common stock ceased trading on the New York Stock Exchange, and former Hospira shareholders became entitled to receive the per share merger consideration of $90 in cash (without interest and less any applicable withholding taxes) for each share of Hospira common stock they owned as of September 3, 2015.

For Hospira registered shareholders, Pfizer has appointed Computershare Trust Company N.A. as paying agent for payment of the merger consideration. Information concerning the exchange of Hospira shares for the per share merger consideration is being mailed to Hospira registered shareholders, outlining the steps to be taken to obtain the merger consideration. Registered shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact Computershare Trust Company, N.A. at 1-800-546-5141 (within the U.S., its territories and Canada) or +1-781-575-2765 (outside the U.S., its territories and Canada). Hospira shareholders who own shares through a bank, brokerage firm or other nominee (in “street name”), should contact their bank, broker or nominee for further information about receiving the merger consideration.

 

[anonymous]

By Dan Stanton+ 21-Sep-2015
Last updated on 21-Sep-2015 at 12:16 GMT

Pfizer is realigning its manufacturing capabilities as part of a billion dollar plan that could see the company split next year.


One of the world’s largest drugmakers, Pfizer, says it will make a decision whether to split up or not by the fourth quarter of 2016, based on the results of an ongoing restructuring plan which will cost several billion dollars.

“When you restructure what do you do?” CFO Frank D'Amelio asked delegates at the Morgan Stanley Global Healthcare Brokers Conference last week. “You consolidate, you combine, you integrate,”citing examples of historic Pfizer spin-outs Zoetis and Capsugel.

Pfizer launched a $300m (€265m) restructuring project in 2014, however, the scope of the scheme has increased.

In January, the firm announced it was spending a further $400m (€350m) in preparation for a potential split this year (which, incidently, was just a few weeks after it said it would buy Hospira for $17bn.)

“The overall cost of the project would be in the low billions of dollars,” D'Amelio said, adding Pfizer is spending that money in four major areas:

The first is the company’s financial structure and ensuring the tax structure is in place to support two separate companies.

The second area is manufacturing and supply chain, he continued: “We're trying to do work obviously to align our manufacturing capabilities, our supply chain capabilities with the two businesses.”

The third area is regulatory, and ensuring the dossiers are re-registered into the appropriate new legal entities, while the fourth is managing systems to support two separate companies.

Four questions

“What we've said is we would make a decision by no later than the fourth quarter of 2016,” D'Amelio confirmed, based on four questions he said Pfizer is reviewing:

1) Are the businesses executing with excellence and are they operating extremely well inside the Company?

2) Will they continue to execute with excellence on a standalone basis?

3) Is there an opportunity to unlock trapped value?

4) Can [Pfizer] unlock that trapped value in an efficient way?

“Those are the four questions, the answer to all four questions needs to be yes.”

 

[anonymous]

By Fiona Barry + 27-Jan-2015
Last updated on 28-Jan-2015 at 12:08 GMT

Pfizer says it is considering breaking up the company in 2015, or alternatively continuing its pursuit of a major acquisition.


Preparing the business for “a potential split of the company” will cost $400m in “one-time costs” in 2015, CEO Ian Read told investors in a call today.

Frank D’Amelio, CFO, said the decision on whether to break up the company would depend on finding a tax-efficient way to do so, as well as the performance of Pfizer’s businesses and confidence levels that they can perform on a stand-alone basis.

If the company pursues M&As instead of a split, any acquisition would be “biased towards deals with the potential for creating value in the near term,” CEO Ian Read told investors in a call today.

Tax inversions – still an M&A motive?

Pfizer made its overtures to AstraZeneca in 2014, partly, Read said during the call, to facilitate a tax inversion, given the more favourable UK rates.

With the US Treasury contemplating tightening tax inversion rules, an investor asked whether inversions will still be a factor for Pfizer when it considers acquisitions.

Read said inversions have not been stopped, but that the US government has delayed the gains companies can receive.

“So inversions are being tempered by the ability to pay the market price given the slow realization of the inversion value.” For as long as the practice is possible, “it’s an area that will remain fertile,” he said, given the US’s “uncompetitive” tax code.

For the moment, it is only “more problematic to plan inversions. We’ll just have to work around that,” said Read.

Read added that he was “a little mystified” by investors’ assumptions that “Pfizer needs to do a deal.”

“I never said we had to do a deal. If I thought there was pressure to do a deal, I would have done one last year.”

But he stressed that Pfizer has the clout to pull off a big M&A. “I do feel we have the ability and the balance sheet we can use if business development can further our strategies.”

Rumours arose this week that Pfizer offered to buy generics giant Teva late last year. Both companies told BioPharma-Reporter.com they would not comment on the speculation.

 

[anonymous]

By Dan Stanton+ 21-Sep-2015
Last updated on 21-Sep-2015 at 12:16 GMT

Pfizer is realigning its manufacturing capabilities as part of a billion dollar plan that could see the company split next year.


One of the world’s largest drugmakers, Pfizer, says it will make a decision whether to split up or not by the fourth quarter of 2016, based on the results of an ongoing restructuring plan which will cost several billion dollars.

“When you restructure what do you do?” CFO Frank D'Amelio asked delegates at the Morgan Stanley Global Healthcare Brokers Conference last week. “You consolidate, you combine, you integrate,”citing examples of historic Pfizer spin-outs Zoetis and Capsugel.

Pfizer launched a $300m (€265m) restructuring project in 2014, however, the scope of the scheme has increased.

In January, the firm announced it was spending a further $400m (€350m) in preparation for a potential split this year (which, incidently, was just a few weeks after it said it would buy Hospira for $17bn.)

“The overall cost of the project would be in the low billions of dollars,” D'Amelio said, adding Pfizer is spending that money in four major areas:

The first is the company’s financial structure and ensuring the tax structure is in place to support two separate companies.

The second area is manufacturing and supply chain, he continued: “We're trying to do work obviously to align our manufacturing capabilities, our supply chain capabilities with the two businesses.”

The third area is regulatory, and ensuring the dossiers are re-registered into the appropriate new legal entities, while the fourth is managing systems to support two separate companies.

Four questions

“What we've said is we would make a decision by no later than the fourth quarter of 2016,” D'Amelio confirmed, based on four questions he said Pfizer is reviewing:

1) Are the businesses executing with excellence and are they operating extremely well inside the Company?

2) Will they continue to execute with excellence on a standalone basis?

3) Is there an opportunity to unlock trapped value?

4) Can [Pfizer] unlock that trapped value in an efficient way?

“Those are the four questions, the answer to all four questions needs to be yes.”

Pfizer.....Excellence???????? Hahahahahahahahahahahaha. The only excellence Pfizer exhibits is in the dismantling of successful companies because they can't get out of their own way. A parasite and predator that will soon implode on itself. So the answers to the 4 questions is NO......Never!